海圣医疗IPO即将上会 业务根基稳固引期待

Core Viewpoint - Zhejiang Haisheng Medical Devices Co., Ltd. is entering the critical IPO review stage with the Beijing Stock Exchange, focusing on the development, production, and sales of anesthesia and monitoring medical devices [1][3] Group 1: Company Overview - The company has established a product matrix covering three main categories: anesthesia, monitoring, and surgical care, with eight major series including airway and respiratory management, life information monitoring, and spinal and nerve block [1] - Its products are widely used in over a thousand tertiary hospitals and thousands of medical institutions across China, including more than 600 top-tier hospitals such as Peking Union Medical College Hospital and Ruijin Hospital affiliated with Shanghai Jiao Tong University [1] Group 2: Financial and Operational Insights - In response to regulatory inquiries regarding the reasonableness of sales expense ratios, the company clarified that sales expenses are primarily allocated to academic promotion, dealer training, and market channel maintenance, aligning with industry peers like Weili Medical and Sanxin Medical [3] - The company plans to issue up to 11,294,118 shares to unspecified qualified investors, or up to 12,988,235 shares if the overallotment option is fully exercised, ensuring that public shareholders will hold at least 25% of the total share capital post-issuance [3] Group 3: Future Prospects - The raised funds will be used for upgrading and expanding production of emergency medical devices, establishing a research and testing center, and building a marketing service base [3] - With its core products already covering numerous key medical institutions and aligning with industry development trends, the company is expected to enhance its production capacity and technological transformation capabilities, thereby solidifying its competitive advantage in the anesthesia and monitoring medical device sector [3]